Indivior collaborates with Addex to enhance GABA(B) PAMs modulators
Indivior declares collaboration with Addex Pharma to accelerate GABAB positive allosteric modulators (PAMs). It has previously recorded preclinical efficacy in animal models for alcohol use disorder and cocaine use disorder. It provides license to lead candidate ADX71441 i.e. expected to be tried in phase 1. Exclusive global license to backup GABAB PAM compounds are also enumerated in the deal. Discovering additional GABAB PAMs are also a part of the deal.
National Institute on drug abuse recently granted $5.3 million to Addex to combat drug abuse by developing ADX71441 in CUD.
Indivior eyes further research funding over the next two years ensuring commercial viability to cure addiction related disorders and rout it completely.
Shaun Thaxter, CEO of Indivior said, “as part of our leadership position in addiction, among the key priorities we are pursuing is continuing to review and invest in promising new treatments for this chronic and relapsing disease.”
Continuous exposure to drug abuse results in multiple changes in the neurotransmitter systems. Research reveals exposure to psychostimulants depresses the functioning of the GABAB receptor signaling in the mesolimbic dopaminergic system.
It is noteworthy that orthosteric agonists have limited tolerance causing adverse effects like sedation, myorelaxing activity and hypothermia. Positive allosteric modulators (PAMs) however, work by only enhancing the activity of GABAB receptors physiologically having less adverse effects rendering it appropriate for persistent treatment.